Publications by authors named "Yulia Vyzhga"
Objective: To evaluate rates of clinically inactive disease (CID) and remission in patients with juvenile idiopathic arthritis (JIA) receiving tofacitinib using the 2021 Juvenile Arthritis Disease Activity Score (JADAS) thresholds and American College of Rheumatology (ACR) criteria.
Methods: This post hoc analysis included patients with active JIA (polyarticular-course JIA, psoriatic arthritis, or enthesitis-related arthritis) enrolled in a phase III randomized withdrawal study of tofacitinib. In part 1 (weeks 0-18), patients received open-label tofacitinib.
Objectives: The aim of the study was to establish an international multicenter registry to collect data on patients with Multisystem Inflammatory Syndrome in Children (MIS-C), in order to highlight a relationship between clinical presentation, age of onset and geographical distribution on the clinical outcome.
Study Design: Multicenter retrospective study involving different international societies for rare immunological disorders.1009 patients diagnosed with MIS-C between March and September 2022, from 48 centers and 22 countries were collected.
Article Synopsis
- - The study assessed safety events in patients with Autoinflammatory diseases using data from the Eurofever registry, focusing on adverse events (AEs) reported since 2009.
- - A total of 2464 patients were included in the analysis, highlighting that 479 AEs were reported, with serious AEs and drug-related AEs being particularly noted, especially in relation to biologic DMARDs and colchicine.
- - The findings underscore the need for consistent monitoring of AEs in rare conditions to better understand the safety of treatments.
Article Synopsis
- - The study aimed to establish and validate specific cutoff values for the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10) to differentiate between various disease activity levels in children with systemic juvenile idiopathic arthritis.
- - Researchers used data from 400 patients across multiple countries, applying different methods to determine these cutoffs, ensuring robust validation through comparison of physician assessments.
- - The identified cutoffs were found to effectively separate inactive disease, minimal disease activity, moderate disease activity, and high disease activity, making them reliable for clinical use and research purposes.
Background: Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA).
Methods: This double-blind, withdrawal phase 3 trial enrolled patients with polyarticular course JIA (extended oligoarthritis, rheumatoid factor-positive or rheumatoid factor-negative polyarthritis, or systemic JIA without active systemic features) aged 2 years to younger than 18 years, and was done at 64 centres of the Paediatric Rheumatology International Trials Organisation and Pediatric Rheumatology Collaborative Study Group networks in 14 countries.